All In Biotech

Drug Trial Radar · NCT07762027

A Study to Assess the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Participants With Chronic Hepatitis D Virus Infection

A Phase 2, Multicenter, Open Label, Parallel-Group Study of the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Participants With Chronic Hepatitis D Virus Infection

Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Oct 2026

Primary completion

Jun 2027

Study completion Sep 2028

Sponsor

Lead sponsor
Assembly BiosciencesIndustry
Sponsor type
Industry
First posted
Aug 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to assess safety, pharmacokinetics, and efficacy ABI-6250 in participants with Chronic Hepatitis D Virus Infection.

Conditions

  • Chronic Hepatitis D Infection

Interventions

  • ABI-6250Drug

    Once daily tablet dosing for 48 weeks starting at Day 1 visit

  • ABI-6250Drug

    Once daily tablet dosing for 48 weeks, starting at Week 16 visit

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects with adverse events (AEs), premature treatment discontinuation and abnormal laboratory results.Time frame: Through study completion, an average of 1.5 years.
  2. Evaluating the change from baseline in HDV RNA & ALT levelsTime frame: Through study completion, an average of 1.5 years.

Locations

22 sites in 11 countries. Site status is shown where the registry gives one.

  • AP-HP - Beaujon Hospital

    Clichy, France

  • Hôpital Henri-Mondor

    Créteil, France

  • CHU Lyon - Hôpital Croix-Rousse

    Lyon, France

  • LLC Neolab

    Tbilisi, Georgia

  • Universitätsklinikum Hamburg-Eppendorf

    Hamburg, Germany

  • Medizinische Hochschule Hannover

    Hanover, Germany

  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico

    Milan, Italy

  • Azienda Ospedaliera Universitaria

    Naples, Italy

  • Clinical Republican Hospital

    Chisinau, Moldova

  • New Zealand Clinical Research

    Auckland, New Zealand

  • Aga Khan University Hospital

    Karachi, Pakistan

  • Dr. Ziauddin Hospital

    Karachi, Pakistan

  • Arensia Research Clinic

    Bucharest, Romania

  • Dr. Victor Babes Foundation

    Bucharest, Romania

  • Fundeni Clinical Institute

    Bucharest, Romania

  • Prof. Dr. Matei Bals National Institute of Infectious Diseases

    Bucharest, Romania

  • Hospital Clínico Universitario Lozano Blesa

    Zaragoza, Spain

  • ARENSIA Exploratory Medicine Ivano-Frankivsk

    Ivano-Frankivsk, Ukraine

  • Medical Center of LLC ARENSIA Exploratory Medicine

    Kyiv, Ukraine

  • King's College Hospital London

    London, United Kingdom

  • The Royal London Hospital

    London, United Kingdom

  • North Manchester General Hospital

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.